Overview
Drug-induced epidermolysis bullosa acquisita (EBA) is a rare autoimmune blistering disorder characterized by subepidermal blistering due to autoantibodies targeting type VII collagen, often triggered by certain medications 1.Diagnosis
Clinical presentation includes widespread subepidermal blisters and erosions 1.
Autoantibodies against type VII collagen confirmed via indirect immunofluorescence or ELISA 1.
Histopathological examination showing subepidermal blistering with a predominantly neutrophilic infiltrate 1.Management
Discontinuation of the suspected drug is critical 1.
Systemic corticosteroids are often used as first-line therapy 1.
Immunosuppressive agents such as azathioprine or mycophenolate mofetil may be adjunctive 1.
Supportive care includes wound management, pain control, and nutritional support 1.Special Populations
Pregnancy: Specific management guidelines not addressed in provided abstracts 1.
Pediatrics: No specific details provided in the abstracts 1.
Elderly: Considerations for comorbidities and treatment tolerance not explicitly detailed 1.
Comorbidities: Management complexities due to coexisting conditions like esophageal stricture noted, requiring multidisciplinary care 1.Key Recommendations
Discontinue the offending medication immediately upon suspicion of drug-induced EBA (Evidence: Expert opinion 1).
Initiate systemic corticosteroids for controlling blistering and inflammation (Evidence: Expert opinion 1).
Consider immunosuppressive therapy for refractory cases to manage disease activity (Evidence: Expert opinion 1).References
1 Lalić H. Discrepancies in the evaluation of incapacity for work in a patient with epidermolysis bullosa acquisita between public pension fund and occupational medicine expert raise the issue of competencies. Arhiv za higijenu rada i toksikologiju 2018. link
2 Wokovich AM, Prodduturi S, Doub WH, Hussain AS, Buhse LF. Transdermal drug delivery system (TDDS) adhesion as a critical safety, efficacy and quality attribute. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 2006. link